Mochi Health vs SkinnyRx (2026): prices, structure, verdict

On tirzepatide, Mochi Health↗ is cheaper: $278 versus $299 a month all-in — a $21 monthly gap, $252 across a year of maintenance dosing.

Updated 2026-08-10 · figures captured 2026-08-09 · how we verify

On semaglutide, Mochi Health is cheaper: $178 versus $199 a month all-in — a $21 monthly gap, $252 across a year of maintenance dosing.

§ Side by side

§ Each record, read aloud

The two records, condensed

Mochi Health: the record, condensed

On tirzepatide, the number that matters at Mochi Health is $278 a month all-in — the figure at the 10 mg maintenance basis this whole site ranks on. Because pricing is flat across the ladder (2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available)), a dose increase at Mochi Health is a clinical event and not a billing one. Whatever your prescriber decides, the invoice does not move, which makes this one of the few programs whose headline figure you can actually plan a year around.

A required $79/month membership is part of the deal, and part of the figure above: $199 of medication plus $79 of platform equals the $278 that leaves your account. Judge the membership by what it includes, but compare on the total.

Context for that figure: it ranks #4 of 17 in the verified tirzepatide index — $63/month above the floor (NexLife↗, $215) — and sits $171 under the brand benchmark (Zepbound (LillyDirect↗), $449 at maintenance). Annualized, a monthly-billed year here runs $3,336.

Start with the load-bearing figure: $178 a month, all-in, is what Mochi Health charges for semaglutide at the 2.4 mg basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

A required $79/month membership is part of the deal, and part of the figure above: $99 of medication plus $79 of platform equals the $178 that leaves your account. Judge the membership by what it includes, but compare on the total.

To place the number: #8 of 20 verified programs, with the floor $45/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare↗)) sits at $349, so the compounded case here is worth $171 a month. A year at this figure: $2,136 monthly-billed.

Operationally at Mochi Health: shipping included; commitment membership recurs monthly; cancellation cancel membership any time; recurs until cancelled; pharmacy named (company-owned compounding facility); states: most states; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the Mochi Health page · visit Mochi Health ↗

SkinnyRx: the record, condensed

Start with the load-bearing figure: $299 a month, all-in, is what SkinnyRx charges for tirzepatide at the 10 mg basis. It is a flat structure: 2.5 → 5 → 7.5 → 10 mg (12.5 and 15 mg available) all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

The absence worth noticing: no mandatory membership. Across this index memberships run $25–$145 a month and hide outside headline prices; here the headline is the bill.

Context for that figure: it ranks #7 of 17 in the verified tirzepatide index — $84/month above the floor (NexLife, $215) — and sits $150 under the brand benchmark (Zepbound (LillyDirect), $449 at maintenance). Annualized, a monthly-billed year here runs $3,588.

Start with the load-bearing figure: $199 a month, all-in, is what SkinnyRx charges for semaglutide at the 2.4 mg basis. It is a flat structure: 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg all bill identically. In a market where most low advertised prices quietly belong to the starter dose, a flat figure is the difference between a quote and a teaser.

Nothing recurs on top: no membership, no platform fee, no “provider access” line. The $199 is the whole subscription, which makes SkinnyRx unusually easy to compare and unusually easy to leave.

To place the number: #11 of 20 verified programs, with the floor $66/month below at Oak Longevity ($133); the approved-product yardstick (Wegovy (NovoCare)) sits at $349, so the compounded case here is worth $150 a month. A year at this figure: $2,388 monthly-billed.

Operationally at SkinnyRx: shipping included; commitment none; cancellation no membership on compounded programs; pharmacy not publicly named — ask in writing before paying; states: not published; evidence source-verified, captured 2026-08-05. The full record with source and archive links: the SkinnyRx page · visit SkinnyRx ↗

Tirzepatide: the duel in full

The tirzepatide arithmetic between these two is short: $278 (Mochi Health) against $299 (SkinnyRx). $21 a month sounds survivable; $252 a year is a decision.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $21 gap is exactly what it appears to be.

Mochi Health’s total includes a mandatory $79/month membership; SkinnyRx has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

Semaglutide: the duel in full

Put the two semaglutide figures side by side and hold them there: Mochi Health at $178, SkinnyRx at $199 — a $21 monthly spread that compounds to $252 over a maintenance year and $504 over two.

Both figures are dose-flat, which is the cleanest possible comparison: two ceilings, no titration surprises on either side, and the $21 gap is exactly what it appears to be.

Mochi Health’s total includes a mandatory $79/month membership; SkinnyRx has none. The all-in figures above neutralize that difference — but the membership side has an exit consideration the other lacks: a fee that recurs until you affirmatively cancel it.

Translate the $21/month spread into medication: $252 a year equals roughly 0.9 months of therapy at the cheaper program’s rate. That is the honest unit for gaps in this market — months of treatment, not abstract dollars — and it is why small-looking monthly differences decide long courses.

On best published rate — the lower of each program’s month-to-month price and its labeled 12-month-plan rate, which is the sort most price roundups quietly run — the duel reads: Mochi Health $278/mo month-to-month versus SkinnyRx $299/mo month-to-month. Same winner on both bases — Mochi Health leads whether you compare month-to-month prices or committed-plan rates, which makes this one of the cleaner verdicts in the index. Prepaid rates are upfront commitments with refund terms to verify before they count.

§ The clock, run forward

Three, six, twelve, twenty-four months — best path each way

3 months: Mochi Health $834 monthly; SkinnyRx $897 monthly — best path favors Mochi Health by $63. 6 months: Mochi Health $1,668 monthly; SkinnyRx $1,794 monthly — best path favors Mochi Health by $126. 12 months: Mochi Health $3,336 monthly; SkinnyRx $3,588 monthly — best path favors Mochi Health by $252. 24 months: Mochi Health $6,672 monthly; SkinnyRx $7,176 monthly — best path favors Mochi Health by $504.

Prepaid paths above are billed upfront and assume the published rate holds (the 24-month figures extend the 12-month rate, an assumption worth naming). The honest reading: over short horizons the monthly gap decides; over long horizons the prepaid ladders and structural traps (dose tiers, memberships) take over — which is exactly the split the verdict section below scores.

The same clock, on semaglutide

3 mo: Mochi Health $534 vs SkinnyRx $597 — $63 to Mochi Health. 6 mo: Mochi Health $1,068 vs SkinnyRx $1,194 — $126 to Mochi Health. 12 mo: Mochi Health $2,136 vs SkinnyRx $2,388 — $252 to Mochi Health. 24 mo: Mochi Health $4,272 vs SkinnyRx $4,776 — $504 to Mochi Health.

Same rules as above: prepaid figures are upfront commitments, and the 24-month lines extend the 12-month rate as a stated assumption. Where the two molecules crown different winners between these two programs, that split is itself the finding — molecule choice and provider choice are separate decisions.

§ Structure vs structure

Everything besides the price

Coverage: Mochi Health publishes “most states”; SkinnyRx publishes “not published” — for anything short of an explicit 50-state claim, intake is the final word.

Pharmacy transparency splits them: Mochi Health names its network (company-owned compounding facility); SkinnyRx does not, which shifts the burden of verification onto your intake questions.

Exit terms: Mochi Health — membership recurs monthly; cancel membership any time; recurs until cancelled. SkinnyRx — none; no membership on compounded programs.

Evidence: Mochi Health source-verified (captured 2026-08-05); SkinnyRx source-verified (2026-08-05).

A rule that has held across this index: disclosure predicts disclosure. Whichever of these two publishes more — pharmacies, states, exit terms — is usually the one whose invoice matches its ad.

In the full tirzepatide index these two sit at #4 and #7 of 17: between them lie 2 other programs, and the whole ladder is at cheapest tirzepatide providers. In the full semaglutide index these two sit at #8 and #11 of 20: between them lie 2 other programs, and the whole ladder is at cheapest semaglutide providers.

§ If you move

Switching between Mochi Health and SkinnyRx

Prescriptions do not transfer like phone numbers: moving in either direction means completing the destination’s intake and having its prescriber write a new patient-specific prescription. The mechanics that prevent a bad month: confirm the destination serves your state and quotes your current dose in writing before cancelling anything; time the first new shipment to overlap the last old one rather than gap it; cancel the origin per its published terms (Mochi Health: cancel membership any time; recurs until cancelled; SkinnyRx: no membership on compounded programs) and screenshot the confirmation; and never leave a prepaid balance stranded — which is the standing argument for prepaying only after a program has already earned a few monthly cycles.

§ Verdict by situation

Which one, for whom

§ More pairings